LXEO 10-Q: SEC filing
Lexeo Therapeutics
Filed with the SEC on · accession 0001193125-26-462020
LXEO filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Lexeo Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing routine financial results, financing activities including October 2025 public offering and private placement, and various license and research agreements.
Key details
✦ Ask GOAX AI about this filing — what it means for LXEO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for LXEO?
Click hereFrequently asked questions
What did LXEO file with the SEC on Nov 16, 2026?
LXEO filed a 10-Q (SEC filing). Lexeo Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing routine financial results, financing activities including October 2025 public offering and private placement, and various license and research agreements.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other LXEO SEC filings
- 8-K · SEC filingNov 16, 2026
- SCHEDULE 13G/A · SEC filingNov 13, 2026
- SCHEDULE 13G · SEC filingNov 10, 2026
- EFFECT · SEC filingNov 4, 2026
- S-3 · Shelf registrationOct 29, 2026
- SCHEDULE 13G · SEC filingOct 13, 2026
- 8-K · AcquisitionSep 29, 2026
- 8-K · AcquisitionSep 22, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
Get alerts when LXEO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days